背景:葛根是两种葛根的干燥根的通用名称。洛巴塔(威尔德。)Maesen&S.M.Almeida前Sanjappa&Predeep(syn.葛根(willd.)Ohwi)或蒙大拿州葛根。thomsonii(Benth.)M.R.阿尔梅达(syn.葛根.).葛根素是从葛根中提取的异黄酮大豆苷元的C-葡萄糖苷。已广泛研究以探索其在眼部疾病中的治疗作用和分子机制。
目的:收集2000年至2022年葛根素治疗眼部疾病的现有文献,并提出未来提高其药用价值的方向。
方法:这篇综述的内容来自WebofScience等数据库,PubMed,谷歌学者,中国国家知识基础设施(CNKI),和万方数据库。
结果:搜索产生了428篇文章,其中,在排除重复文章和与葛根素相关但与评论主题不太相关的文章后,纳入了159篇文章。在11篇文章中,讨论了葛根素的生物利用度。尽管葛根素具有多种生物活性,它本身的生物利用度很差。有95篇文献报道了葛根素在眼部疾病中的治疗机制。其中,54篇文章讨论了葛根素影响的各种与眼病相关的信号通路。另外41篇文章讨论了葛根素的具体生物学活性。它通过调节核因子κB(NF-κB)在眼病中起治疗作用,丝裂原活化蛋白激酶(MAPK),PI3K/AKT,JAK/STAT,蛋白激酶C(PKC)和其他相关通路,影响肿瘤坏死因子α(TNF-α)的表达,白细胞介素-1β(IL-1β),细胞间粘附分子-1(ICAM-1),单核细胞趋化蛋白-1(MCP-1),超氧化物歧化酶(SOD),B细胞淋巴瘤-2(Bcl-2)和其他细胞因子导致抗炎,抗氧化和抗凋亡作用。25篇文献讨论了葛根素在眼科的临床应用。11篇文章讨论了葛根素的毒性。文献表明葛根素具有良好的疗效,可安全用于临床。
结论:本综述阐述了葛根素在眼部疾病中的多种应用,提示葛根素可用于糖尿病视网膜病变的治疗。视网膜血管阻塞,青光眼等眼部疾病的临床应用。一些眼部疾病是多种因素共同作用的结果,葛根素对不同因素的影响有待进一步研究,以完善葛根素更完整的作用机制。此外,有必要增加临床试验的受试者数量,并进行其他眼部疾病的临床试验。这里提供的信息将指导未来的研究。
BACKGROUND: Pueraria is the common name of the dried root of either Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep (syn. Pueraria lobata (Willd.) Ohwi) or Pueraria montana var. thomsonii (Benth.) M.R.Almeida (syn. Pueraria thomsonii Benth.). Puerarin is a C-glucoside of the isoflavone daidzein extracted from Pueraria. It has been widely investigated to explore its therapeutic role in eye diseases and the molecular mechanisms.
OBJECTIVE: To collect the available literature from 2000 to 2022 on puerarin in the treatment of ocular diseases and suggest the future required directions to improve its medicinal value.
METHODS: The content of this
review was obtained from databases such as Web of Science, PubMed, Google Scholar, China National Knowledge Infrastructure (CNKI), and the Wanfang Database.
RESULTS: The search yielded 428 articles, of which 159 articles were included after excluding duplicate articles and articles related to puerarin but less relevant to the topic of the
review. In eleven articles, the bioavailability of
puerarin was discussed. Despite puerarin possesses diverse biological activities, its bioavailability on its own is poor. There are 95 articles in which the therapeutic mechanisms of puerarin in ocular diseases was reported. Of these, 54 articles discussed the various signalling pathways related to occular diseases affected by puerarin. The other 41 articles discussed specific biological activities of puerarin. It plays a therapeutic role in ophthalmopathy via regulating nuclear factor kappa-B (NF-ĸB), mitogen-activated protein kinases (MAPKs), PI3K/AKT, JAK/STAT, protein kinase C (PKC) and other related pathways, affecting the expression of tumour necrosis factor α (TNF-α), interleukin-1β (IL-1β), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), superoxide dismutase (SOD), B-cell lymphoma-2 (Bcl-2) and other cytokines resulting in anti-inflammatory, antioxidant and anti-apoptotic effects. The clinical applications of puerarin in ophthalmology were discussed in 25 articles. Eleven articles discussed the toxicity of
puerarin. The literature suggests that puerarin has a good curative effect and can be used safely in clinical practice.
CONCLUSIONS: This
review has illustrated the diverse applications of
puerarin acting on ocular diseases and suggested that puerarin can be used for treating diabetic retinopathy, retinal vascular occlusion, glaucoma and other ocular diseases in the clinic. Some ocular diseases are the result of the combined action of multiple factors, and the effect of puerarin on different factors needs to be further studied to improve a more complete mechanism of action of puerarin. In addition, it is necessary to increase the number of subjects in clinical trials and conduct clinical trials for other ocular diseases. The information presented here will guide future research studies.